Stock Events

Stock Events

Solid Biosciences 

$7.36
64
+$0.22+3.08% Today

Statistics

Day High
7.48
Day Low
7.11
52W High
8.87
52W Low
3.79
Volume
2,060,110
Avg. Volume
1,126,188
Mkt Cap
573.42M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-1
-0.81
-0.61
-0.42
Expected EPS
-0.457574
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-249.39MNet Income

Analyst Ratings

18.83Average Price Target
The highest estimate is 26.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SLDB. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap1.62B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases, including Duchenne muscular dystrophy (DMD), directly competing with Solid Biosciences' gene therapy approaches for DMD.
PTC Therapeutics
PTCT
Mkt Cap5.88B
PTC Therapeutics is involved in the development of genetically targeted therapies for the treatment of rare diseases, including DMD, positioning it as a competitor in the same therapeutic area as Solid Biosciences.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.81B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including therapies for DMD, making it a direct competitor in the rare disease space.
Pfizer
PFE
Mkt Cap149.38B
Pfizer is engaged in the discovery, development, manufacture, and sale of healthcare products, including gene therapies for rare diseases. Its broad focus on gene therapy research can potentially compete with Solid Biosciences' DMD treatments.
Sangamo Therapeutics
SGMO
Mkt Cap62.14M
Sangamo Therapeutics focuses on genomic medicine, including gene therapy, gene editing, and gene regulation, to develop treatments for DMD among other diseases, positioning it as a competitor in the gene therapy space.
Dyadic International DE
DYAI
Mkt Cap25.47M
Dyadic International leverages its proprietary C1 gene expression platform to develop and produce biologic vaccines and drugs at flexible scales, including potential treatments for rare diseases, which may compete with Solid Biosciences' therapeutic approaches.
Ultragenyx Pharmaceutical
RARE
Mkt Cap2.16B
Ultragenyx Pharmaceutical focuses on the development of novel products for serious rare and ultra-rare genetic diseases, including muscle-related disorders, which could compete with Solid Biosciences' pipeline.
Abeona Therapeutics
ABEO
Mkt Cap315.18M
Abeona Therapeutics is focused on developing gene and cell therapies for life-threatening rare genetic diseases, including DMD, making it a direct competitor in the gene therapy market.
Novartis
NVS
Mkt Cap292.07B
Novartis is a global healthcare company that, through its acquisition of AveXis, has entered the gene therapy market for spinal muscular atrophy and is exploring treatments for other genetic disorders, potentially competing with Solid Biosciences in the broader gene therapy market.

About

Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
Show more...
CEO
Mr. Ian F. Smith A.C.A., C.P.A.
Employees
100
Country
United States
ISIN
US83422E2046

Listings

MU
DE
B6C.MU
XNAS
US
SLDB
BOATS
BOATS
SLDB.BOATS

0 Comments

Share your thoughts

FAQ

What is Solid Biosciences stock price today?▼
The current price of SLDB is $7.36 USD — it has increased by +3.08% in the past 24 hours. Watch Solid Biosciences stock price performance more closely on the chart.
What is Solid Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Solid Biosciences stocks are traded under the ticker SLDB.
Is Solid Biosciences stock price growing?▼
SLDB stock has risen by +14.82% compared to the previous week, the month change is a +6.36% rise, over the last year Solid Biosciences has showed a +63.19% increase.
What is Solid Biosciences market cap?▼
Today Solid Biosciences has the market capitalization of 573.42M
When is the next Solid Biosciences earnings date?▼
Solid Biosciences is going to release the next earnings report on August 17, 2026.
What were Solid Biosciences earnings last quarter?▼
SLDB earnings for the last quarter are -0.52 USD per share, whereas the estimation was -0.43 USD resulting in a -21.32% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Solid Biosciences revenue for the last year?▼
Solid Biosciences revenue for the last year amounts to 0 USD.
What is Solid Biosciences net income for the last year?▼
SLDB net income for the last year is -249.39M USD.
How many employees does Solid Biosciences have?▼
As of June 15, 2026, the company has 100 employees.
In which sector is Solid Biosciences located?▼
Solid Biosciences operates in the Health & Wellness sector.
When did Solid Biosciences complete a stock split?▼
The last stock split for Solid Biosciences was on October 28, 2022 with a ratio of 1:15.
Where is Solid Biosciences headquartered?▼
Solid Biosciences is headquartered in Charlestown, United States.